Biohaven (NYSE:BHVN – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.56) ...
The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
Amy Candido joins Simpson Thacher after more than three years as a partner at Wilson Sonsini Goodrich & Rosati.
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
New weight-loss treatments are being developed to preserve or increase muscle mass while shedding pounds. Companies like Eli Lilly, Regeneron, and Roche are focusing on therapies that target proteins ...
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results